Europe’s health policies ‘must change’ with stakeholders leaving their ‘comfort zones’
24 Oct 2014
“Patients are waiting for therapeutic improvement and asking us – while we have good technologies – are we really bringing them the best new drugs? And if we look hard in the mirror the fact is that we are not using technology optimally”, said Dr. Denis Lacombe, EORTC Director. “There needs to be more collaboration, new models…and that means we have to think outside the box.”
Read the entire interview here
Related News
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research
20 May 2026
Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer
17 May 2026
Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma
1 May 2026
EORTC’s presence at ESTRO 2026
30 Apr 2026
Interview of ROSC Chair, Joost Vaerhoeff
28 Apr 2026
Independent, academic cancer trials are vital to improve patient outcomes worldwide
28 Apr 2026
